A61K31/167

Methods and compositions for treating female sexual interest and arousal disorder
11701332 · 2023-07-18 ·

Provided herein are compositions, methods and kits for effectively preventing, treating, reducing, mitigating, or controlling FSIAD.

GOLF BALL-LIKE MICROPARTICLES FOR USE IN THE TREATMENT AND PREVENTION OF PULMONARY DISEASES
20230218515 · 2023-07-13 ·

The present invention relates to a golf ball-like microparticles obtained by atomization of nanosuspensions of nanoparticles or solutions for dry powder inhalers for use in the treatment and prevention of pulmonary diseases.

GOLF BALL-LIKE MICROPARTICLES FOR USE IN THE TREATMENT AND PREVENTION OF PULMONARY DISEASES
20230218515 · 2023-07-13 ·

The present invention relates to a golf ball-like microparticles obtained by atomization of nanosuspensions of nanoparticles or solutions for dry powder inhalers for use in the treatment and prevention of pulmonary diseases.

METHOD FOR INCORPORATING ORGANIC COMPOUNDS IN SOLUTION WITHIN A HYDROGEL
20230218520 · 2023-07-13 · ·

A method for incorporating at least one organic compound within a hydrogel, wherein the incorporation is carried out by dialysis, the organic compound being solubilized in the dialysis solution at a concentration equal to or greater than the target concentration.

METHOD FOR INCORPORATING ORGANIC COMPOUNDS IN SOLUTION WITHIN A HYDROGEL
20230218520 · 2023-07-13 · ·

A method for incorporating at least one organic compound within a hydrogel, wherein the incorporation is carried out by dialysis, the organic compound being solubilized in the dialysis solution at a concentration equal to or greater than the target concentration.

Acetaminophen Formulation With Protection Against Toxic Effects of Overdose
20230218552 · 2023-07-13 ·

An oral pharmaceutical dosage form that comprises both acetaminophen and a glutathione replenishing agent, such as N-acetylcysteine. This allows co-administering the glutathione replenishing agent along with acetaminophen, which may be beneficial in rapidly counteracting the toxic effects of acetaminophen overdose. The oral dosage form could be in the form of a tablet or capsule. The dosage form may be designed to compartmentally separate the glutathione replenishing agent from having chemical interaction with the acetaminophen. The dosage form may be designed to mask the taste or smell of the glutathione replenishing agent.

Acetaminophen Formulation With Protection Against Toxic Effects of Overdose
20230218552 · 2023-07-13 ·

An oral pharmaceutical dosage form that comprises both acetaminophen and a glutathione replenishing agent, such as N-acetylcysteine. This allows co-administering the glutathione replenishing agent along with acetaminophen, which may be beneficial in rapidly counteracting the toxic effects of acetaminophen overdose. The oral dosage form could be in the form of a tablet or capsule. The dosage form may be designed to compartmentally separate the glutathione replenishing agent from having chemical interaction with the acetaminophen. The dosage form may be designed to mask the taste or smell of the glutathione replenishing agent.

Acetaminophen Formulation With Protection Against Toxic Effects of Overdose
20230218552 · 2023-07-13 ·

An oral pharmaceutical dosage form that comprises both acetaminophen and a glutathione replenishing agent, such as N-acetylcysteine. This allows co-administering the glutathione replenishing agent along with acetaminophen, which may be beneficial in rapidly counteracting the toxic effects of acetaminophen overdose. The oral dosage form could be in the form of a tablet or capsule. The dosage form may be designed to compartmentally separate the glutathione replenishing agent from having chemical interaction with the acetaminophen. The dosage form may be designed to mask the taste or smell of the glutathione replenishing agent.

Krüppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney Disease
20230219893 · 2023-07-13 ·

The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Krüppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney Disease
20230219893 · 2023-07-13 ·

The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.